Status:
UNKNOWN
Donepezil, Residual Excessive Daytime Sleepiness, Obstructive Sleep Apnea
Lead Sponsor:
Associação Fundo de Incentivo à Pesquisa
Conditions:
OSA
Sleepiness
Eligibility:
All Genders
35-60 years
Phase:
PHASE4
Brief Summary
It is a randomized, double-blind, single-center, 30-day study. Patients aged 35-60 years, with apnea and hypopnea index and respiratory disturbance index normalized with CPAP, and Epworth Sleepiness S...
Detailed Description
Obstructive Sleep Apnea (OSA) is a sleep-disordered breathing characterized by recurrent episodes of total or partial obstruction of the upper airway during sleep, which can lead to cognitive, metabol...
Eligibility Criteria
Inclusion
- Both gender, Age between 35 and 65 years;
- Confirmed diagnosis of moderate to severe OSA;
- Treatment with CPAP for at least six months;
- Persistent sleepiness with daily CPAP use compliance \> 5 hours per night.
Exclusion
- Neurological or psychiatric diseases;
- Chronic use of psychoactive drugs, other sleep disorders than OSA, visual defficiency, illiteracy.
Key Trial Info
Start Date :
July 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 2 2019
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT03299257
Start Date
July 6 2018
End Date
March 2 2019
Last Update
June 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto do Sono
São Paulo, Brazil, 04024-002